ChemLifeIntel/Companies/Blossom Pharmaceuticals

Blossom Pharmaceuticals

HIGH RISKHQ: — · Private · Founded —

LISTINGPrivateFOUNDED0

FOCUS THERAPY AREAS

Manufacturer

COMPANY INTELLIGENCE SNAPSHOTlive

Manufacturing Sites

Intelligence Briefs

Active Regulatory Actions

—

HQ Country

NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ

View regulatory detail

INTELLIGENCE

Showing 3 of 3 briefs on Blossom Pharmaceuticals

REGULATORY INTELLIGENCE·Recall

Blossom Pharmaceuticals Initiates Nationwide Recall of Zinc Oxide Ointment Due to cGMP Deviations

Blossom Pharmaceuticals has initiated a Class II recall of 912 containers of Zinc Oxide Ointment USP, manufactured for Nivagen Pharmaceuticals, Inc., due to cGMP deviations at its Bardej, Goa, India facility. This nationwide USA recall underscores critical quality control lapses, demanding immediate assessment by procurement and regulatory teams. Decision-makers must evaluate supply chain vulnerabilities and enhance due diligence for contract manufacturing partners, particularly those in India.

90-Day Activity

Blossom PharmaceuticalsNIVAGEN ZINC OXIDE

PSPriya Subramaniam· Intelligence Analyst

2025-12-10

REGULATORY INTELLIGENCE·Recall

Blossom Pharmaceuticals Initiates Nationwide Recall of Zinc Oxide Ointment Over cGMP Deviations

Blossom Pharmaceuticals has initiated a voluntary Class II recall of 33,000 containers of Globe Zinc Oxide Ointment USP 20% due to cGMP deviations at its Bardej, Goa, India facility. This action, impacting USA nationwide distribution by Trifecta Pharmaceuticals USA, signals critical supply chain vulnerabilities and heightened regulatory scrutiny for procurement and regulatory affairs teams managing topical OTC drug portfolios.

90-Day Activity

Blossom PharmaceuticalsDiazoxide Choline

PSPriya Subramaniam· Intelligence Analyst

2025-12-10▲ Trending signal

REGULATORY INTELLIGENCE·Recall

Blossom Pharmaceuticals Initiates Class II Recall of Dynashield Skin Protectant Over cGMP Deviations in India

Blossom Pharmaceuticals has initiated a Class II recall of 1,560 units of Dynashield Skin Protectant (Zinc Oxide) due to cGMP deviations at its Bardej, Goa, India facility. This impacts Dynarex Corporation and US nationwide distribution, signaling critical supply chain and regulatory risks for procurement and regulatory affairs teams.

90-Day Activity

Blossom PharmaceuticalsDynashield Skin Protectant

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

2025-12-10